Q2 2024 Bayer AG Earnings Call Transcript
Key Points
- Bayer AG (BAYRY) is advancing towards its target of EUR 2 to 3 billion in free cash flow for the year.
- The company has seen positive developments in litigation, including a favorable decision from the Federal Court of Australia in the Roundup litigation.
- Bayer AG (BAYRY) has launched new products and expanded existing ones, such as Veracast in the U.S. and One A Day in the cellular health field.
- The company has made significant progress in its pharma pipeline, with successful results in recent Phase 3 clinical trials for heart failure and advancements in treatments for Parkinson's disease and non-small cell lung cancer.
- The Consumer Health division has returned to growth, with a 5% increase in sales driven by innovation and improved supply situations.
- Bayer AG (BAYRY) faced a EUR 240 million foreign exchange headwind, impacting reported sales growth.
- EBITDA before special items declined by 16% compared to the prior year quarter, largely due to an unfavorable mix effect in Crop Science and higher provisions for short-term incentives.
- The company is experiencing significant generic pricing pressure in its Crop Protection business, which is expected to continue.
- Sales of Xarelto declined by 11% due to patent expirations and resulting generic competition in Europe and Canada.
- Despite lower earnings, the company still faces high net financial debt, which stood at EUR 36.8 billion by the end of Q2.
Please stand by for streaming text.
Consumers with trust and self-care. That's a step change from where we are today. And it will require quality growth through innovation, expansion of new brands and the right portfolio choices. That's why we're taking brands Veracast, a beloved gut health treatment, and we're expanding it to the U.S. We're launching one a day into the emerging field of cellular. Now to litigation on PCBs. We had some news at the end of July that I'd like to put in context.
You might remember that in 2020, we communicated a nationwide class settlement with 25 hundred local governments. Some municipalities opted out. Seattle was one of them a unique case with special circumstances as it involves claims not present in the other opt-outs. Ciena settlement here is significant.
Overall there nine environmental cases involving municipal plaintiffs that are still pending in each case is different. If we choose to pursue settlements, we expect them to come in at lower terms be on that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
